RxSight (RXST) Long-Term Debt Issuances (2020 - 2021)

RxSight (RXST) reported Long-Term Debt Issuances of $10.0 million for Q2 2021, up 100.0% quarter-over-quarter from $5.0 million in Q1 2021.

RxSight (RXST) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends

RxSight has reported Long-Term Debt Issuances for 2 years, with the latest figure at $10.0 million in Q2 2021.

For the quarter ending Q2 2021, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Sep 2022 stood at $10.0 million (down 75.0% YoY), and the FY2023 full-year result was $20.0 million, changed N/A from the prior year.
Long-Term Debt Issuances for Q2 2021 stood at $10.0 million, up from $5.0 million in the prior quarter.
The five-year high for Long-Term Debt Issuances was $25.0 million in Q4 2020, with the low at $5.0 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	19.86 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	-
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	-
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	-
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	1.15 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	11.71 Mn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-
10	RxSight	193.93 Mn	-23.95 Mn	23.50 Mn	-

Download Data